HER2-TARGETED THERAPIES

Home HER2-Targeted Therapies Videos

Videos

Monitoring and Management Strategies for HER2-Targeted Therapy–Associated Cardiotoxicity

Program Chair Jessica Shank Coviello, DNP, APRN, ANP-BC, and Barbara Rogers, CRNP, MN, AOCN^®, ANP-BC, discuss best practices for monitoring and managing cardiotoxicity associated with HER2-targeted therapies.

CARDIO-ONCOLOGY BASICS

What is Cardio-Oncology?

Link Between Cancer, Treatment, and Heart Disease

Cardio-Oncology Standards of Care

CV Evaluation of Patients Before and During Cancer Therapy

Cancer Treatment–Related Cardiotoxicity

Breast Cancer Drugs and Cardiotoxicity

Cardio-Oncology Basics: Conclusions

Meet the Faculty

Resources

General Cardio-Oncology The Cancer Patient and Cardiology

General Cardio-Oncology The Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio‐Oncology Council of the European Society of Cardiology (ESC)

General Cardio-Oncology Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools From the Cardio-Oncology Study Group of the Heart Failure Association of the European Society

General Cardio-Oncology NCCN Clinical Practice Guidelines in Oncology: Survivorship Version 2.2020

General Cardio-Oncology Cardiovascular and Cancer Risk: The Role of Cardio-Oncology